{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:41:46Z","timestamp":1790019706064,"version":"4.0.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H02846"],"award-info":[{"award-number":["21H02846"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772044"],"award-info":[{"award-number":["81772044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Relapse is common in remitted patients with major depressive disorder (MDD). Arketamine, an (<jats:italic>R<\/jats:italic>)-enantiomer of ketamine, has persistent prophylactic actions in an inflammatory model of depression. However, the precise mechanisms underlying these prophylactic actions remain unknown. Given the role of the brain\u2013spleen axis in depression, we sought to identify splenic molecular targets that play a role in the prophylactic actions of arketamine. Lipopolysaccharide (LPS) (1.0\u2009mg\/kg) was administered 6 days after a single injection of arketamine (10\u2009mg\/kg) or saline. RNA-sequencing analysis found altered expression in the heme biosynthesis II pathway. Quantitative RT-PCR revealed that pretreatment with arketamine blocked increased expression of genes involved in the heme biosynthesis II pathway in LPS-treated mice, namely, 5-aminolevulinase synthase 2 (<jats:italic>Alas2<\/jats:italic>), ferrochelatase (<jats:italic>Fech<\/jats:italic>), hydroxymethylbilane synthase (<jats:italic>Hmbs<\/jats:italic>). Interestingly, there were positive correlations between the expression of these genes and spleen weight or plasma levels of pro-inflammatory cytokines. We also found higher expression of ALAS2 and FECH in the spleen from MDD patients. Pretreatment with a key intermediate precursor of heme, 5-aminolaevulinic acid (300\u2009mg\/kg\/day for 3 days), caused splenomegaly, higher plasma levels of pro-inflammatory cytokines, and depression-like behavior in low-dose LPS (0.1\u2009mg\/kg)-treated mice. Interestingly, pretreatment with a heme biosynthesis inhibitor, succinyl acetone (120\u2009mg\/kg\/day for 3 days), had prophylactic effects in LPS (1.0\u2009mg\/kg)-treated mice. These data suggest a novel role for the heme biosynthesis II pathway in the spleen for inflammation-related depression. Therefore, the heme biosynthesis pathway could be a new target for the prevention of relapse in MDD patients.<\/jats:p>","DOI":"10.1038\/s41398-023-02564-6","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T15:32:06Z","timestamp":1690299126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A role of splenic heme biosynthesis pathway in the persistent prophylactic actions of arketamine in lipopolysaccharide-treated mice"],"prefix":"10.1038","volume":"13","author":[{"given":"Li","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youge","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-0439","authenticated-orcid":false,"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"2564_CR1","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.cpr.2007.02.005","volume":"27","author":"SL Burcusa","year":"2007","unstructured":"Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007;27:959\u201385.","journal-title":"Clin Psychol Rev."},{"key":"2564_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1475-7","volume":"16","author":"CH Liu","year":"2019","unstructured":"Liu CH, Zhang GZ, Li B, Li M, Woelfer M, Walter M, et al. Role of inflammation in depression relapse. J Neuroinflammation. 2019;16:90.","journal-title":"J Neuroinflammation"},{"key":"2564_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.brainresrev.2009.05.005","volume":"61","author":"K Hashimoto","year":"2009","unstructured":"Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev. 2009;61:105\u201323.","journal-title":"Brain Res Rev."},{"key":"2564_CR4","doi-asserted-by":"publisher","first-page":"7796","DOI":"10.3390\/ijms16047796","volume":"16","author":"K Hashimoto","year":"2015","unstructured":"Hashimoto K. Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci. 2015;16:7796\u2013801.","journal-title":"Int J Mol Sci."},{"key":"2564_CR5","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3389\/fphar.2018.01182","volume":"9","author":"K Hashimoto","year":"2018","unstructured":"Hashimoto K. Essential role of Keap1-Nrf2 signaling in mood disorders: overview and future direction. Front Pharmacol. 2018;9:1182.","journal-title":"Front Pharmacol."},{"key":"2564_CR6","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856\u201364.","journal-title":"Arch Gen Psychiatry"},{"key":"2564_CR7","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","volume":"170","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170:1134\u201342.","journal-title":"Am J Psychiatry"},{"key":"2564_CR8","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/npp.2017.94","volume":"42","author":"TP Su","year":"2017","unstructured":"Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, et al. Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017;42:2482\u201392.","journal-title":"Neuropsychopharmacology"},{"key":"2564_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","volume":"106","author":"W Zheng","year":"2018","unstructured":"Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, et al. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. J Psychiatry Res. 2018;106:61\u20138.","journal-title":"J Psychiatry Res"},{"key":"2564_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","volume":"176","author":"JL Phillips","year":"2019","unstructured":"Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry. 2019;176:401\u20139.","journal-title":"Am J Psychiatry"},{"key":"2564_CR11","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","volume":"25","author":"M Fava","year":"2020","unstructured":"Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020;25:1592\u2013603.","journal-title":"Mol Psychiatry"},{"key":"2564_CR12","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.biopsych.2015.04.022","volume":"79","author":"RA Brachman","year":"2016","unstructured":"Brachman RA, McGowan JC, Perusini JN, Lim SC, Pham TH, Faye C, et al. Ketamine as a prophylactic against stress-induced depressive-like behavior. Biol Psychiatry. 2016;79:776\u201386.","journal-title":"Biol Psychiatry"},{"key":"2564_CR13","doi-asserted-by":"publisher","first-page":"112238","DOI":"10.1016\/j.bbr.2019.112238","volume":"378","author":"A Mastrodonato","year":"2020","unstructured":"Mastrodonato A, Cohensedgh O, LaGamma CT, McGowan JC, Hunsberger HC, Denny CA. Prophylactic (R,S)-ketamine selectively protects against inflammatory stressors. Behav Brain Res. 2020;378:112238.","journal-title":"Behav Brain Res."},{"key":"2564_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","volume":"116","author":"JC Zhang","year":"2014","unstructured":"Zhang JC, Li SX, Hashimoto K. R(\u2212)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochem Behav. 2014;116:137\u201341.","journal-title":"Pharmacol Biochem Behav."},{"key":"2564_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.136","volume":"5","author":"C Yang","year":"2015","unstructured":"Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632.","journal-title":"Transl Psychiatry"},{"key":"2564_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1124\/jpet.116.239228","volume":"361","author":"K Fukumoto","year":"2017","unstructured":"Fukumoto K, Toki H, Iijima M, Hashihayata T, Yamaguchi JI, Hashimoto K, et al. Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther. 2017;361:9\u201316.","journal-title":"J Pharmacol Exp Ther."},{"key":"2564_CR17","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.biopsych.2016.12.020","volume":"82","author":"C Yang","year":"2017","unstructured":"Yang C, Qu Y, Abe M, Nozawa D, Chaki S, Hashimoto K. (R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine. Biol Psychiatry. 2017;82:e43\u20134.","journal-title":"Biol Psychiatry"},{"key":"2564_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","volume":"83","author":"C Yang","year":"2018","unstructured":"Yang C, Ren Q, Qu Y, Zhang JC, Ma M, Dong C, et al. Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry. 2018;83:18\u201328.","journal-title":"Biol Psychiatry"},{"key":"2564_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","volume":"181","author":"L Chang","year":"2019","unstructured":"Chang L, Zhang K, Pu Y, Qu Y, Wang SM, Xiong Z, et al. Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacol Biochem Behav. 2019;181:53\u20139.","journal-title":"Pharmacol Biochem Behav."},{"key":"2564_CR20","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/pcn.12902","volume":"73","author":"K Hashimoto","year":"2019","unstructured":"Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci. 2019;73:613\u201327.","journal-title":"Psychiatry Clin Neurosci."},{"key":"2564_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0624-1","volume":"9","author":"C Yang","year":"2019","unstructured":"Yang C, Yang J, Luo A, Hashimoto K. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Transl Psychiatry. 2019;9:280.","journal-title":"Transl Psychiatry"},{"key":"2564_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/14737175.2019.1554434","volume":"19","author":"K Zhang","year":"2019","unstructured":"Zhang K, Hashimoto K. An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Rev Neurother. 2019;19:83\u201392.","journal-title":"Expert Rev Neurother."},{"key":"2564_CR23","doi-asserted-by":"publisher","first-page":"113935","DOI":"10.1016\/j.bcp.2020.113935","volume":"177","author":"K Hashimoto","year":"2020","unstructured":"Hashimoto K. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem Pharmacol. 2020;177:113935.","journal-title":"Biochem Pharmacol."},{"key":"2564_CR24","doi-asserted-by":"publisher","first-page":"172870","DOI":"10.1016\/j.pbb.2020.172870","volume":"190","author":"Y Wei","year":"2020","unstructured":"Wei Y, Chang L, Hashimoto K. A historical review of antidepressant effects of ketamine and its enantiomers. Pharmacol Biochem Behav. 2020;190:172870.","journal-title":"Pharmacol Biochem Behav."},{"key":"2564_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0733-x","volume":"10","author":"K Zhang","year":"2020","unstructured":"Zhang K, Yang C, Chang L, Sakamoto A, Suzuki T, Fujita Y, et al. Essential role of microglial transforming growth factor-\u03b21 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-\u03b21. Transl Psychiatry. 2020;10:32.","journal-title":"Transl Psychiatry"},{"key":"2564_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","volume":"27","author":"Y Wei","year":"2022","unstructured":"Wei Y, Chang L, Hashimoto K. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Mol Psychiatry. 2022;27:559\u201373.","journal-title":"Mol Psychiatry"},{"key":"2564_CR27","doi-asserted-by":"publisher","first-page":"109219","DOI":"10.1016\/j.neuropharm.2022.109219","volume":"218","author":"JC Zhang","year":"2022","unstructured":"Zhang JC, Yao W, Hashimoto K. Arketamine, a new rapid-acting antidepressant: a historical review and future directions. Neuropharmacology. 2022;218:109219.","journal-title":"Neuropharmacology"},{"key":"2564_CR28","doi-asserted-by":"publisher","first-page":"109305","DOI":"10.1016\/j.neuropharm.2022.109305","volume":"222","author":"K Zhang","year":"2023","unstructured":"Zhang K, Yao Y, Hashimoto K. Ketamine and its metabolites: potential as novel treatments for depression. Neuropharmacology. 2023;222:109305.","journal-title":"Neuropharmacology"},{"key":"2564_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.psychres.2016.03.034","volume":"239","author":"C Yang","year":"2016","unstructured":"Yang C, Han M, Zhang JC, Ren Q, Hashimoto K. Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res. 2016;239:281\u20133.","journal-title":"Psychiatry Res"},{"key":"2564_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00406-016-0692-7","volume":"267","author":"K Hashimoto","year":"2017","unstructured":"Hashimoto K, Kakiuchi T, Ohba H, Nishiyama S, Tsukada H. Reduction of dopamine D2\/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci. 2017;267:173\u20136.","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"2564_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pbb.2018.07.003","volume":"172","author":"Z Tian","year":"2018","unstructured":"Tian Z, Dong C, Fujita A, Fujita Y, Hashimoto K. Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine. Pharmacol Biochem Behav. 2018;172:17\u201321.","journal-title":"Pharmacol Biochem Behav."},{"key":"2564_CR32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70:621\u201360.","journal-title":"Pharmacol Rev."},{"key":"2564_CR33","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","volume":"26","author":"J Bonaventura","year":"2021","unstructured":"Bonaventura J, Lam S, Carlton M, Boehm MA, Gomez JL, Sol\u00eds O, et al. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry. 2021;26:6704\u201322.","journal-title":"Mol Psychiatry"},{"key":"2564_CR34","doi-asserted-by":"publisher","first-page":"104762","DOI":"10.1016\/j.neubiorev.2022.104762","volume":"139","author":"X Wang","year":"2022","unstructured":"Wang X, Yang J, Hashimoto K. (R)-ketamine as prophylactic and therapeutic drug for neurological disorders: beyond depression. Neurosci Biobehav Rev. 2022;139:104762.","journal-title":"Neurosci Biobehav Rev."},{"key":"2564_CR35","doi-asserted-by":"publisher","unstructured":"Hashimoto K. Arketamine for cognitive impairment in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci. 2023;1\u201313. https:\/\/doi.org\/10.1007\/s00406-023-01570-5.","DOI":"10.1007\/s00406-023-01570-5"},{"key":"2564_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/bs.pbr.2023.01.003","volume":"278","author":"K Hashimoto","year":"2023","unstructured":"Hashimoto K. Neuroinflammation through the vagus nerve-dependent gut\u2013microbiota\u2013brain axis in treatment-resistant depression. Prog Brain Res. 2023;278:61\u201377.","journal-title":"Prog Brain Res"},{"key":"2564_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01803-6","volume":"12","author":"L Ma","year":"2022","unstructured":"Ma L, Zhang J, Fujita Y, Qu Y, Shan J, Wan X, et al. Nuclear factor of activated T cells 4 in the prefrontal cortex is required for prophylactic actions of (R)-ketamine. Transl Psychiatry. 2022;12:27.","journal-title":"Transl Psychiatry"},{"key":"2564_CR38","doi-asserted-by":"publisher","first-page":"109250","DOI":"10.1016\/j.neuropharm.2022.109250","volume":"219","author":"L Ma","year":"2022","unstructured":"Ma L, Wang L, Chang L, Shan J, Qu Y, Wang X, et al. A role of microRNA-149 in the prefrontal cortex for prophylactic actions of (R)-ketamine in inflammation model. Neuropharmacology. 2022;219:109250.","journal-title":"Neuropharmacology"},{"key":"2564_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02192-6","volume":"12","author":"L Ma","year":"2022","unstructured":"Ma L, Wang L, Chang L, Shan J, Qu Y, Wang X, et al. A key role of miR-132-5p in the prefrontal cortex for persistent prophylactic actions of (R)-ketamine in mice. Transl Psychiatry. 2022;12:417.","journal-title":"Transl Psychiatry"},{"key":"2564_CR40","doi-asserted-by":"publisher","first-page":"109345","DOI":"10.1016\/j.neuropharm.2022.109345","volume":"224","author":"BK Chen","year":"2023","unstructured":"Chen BK, Denny CA. Weapons of stress reduction: (R,S)-ketamine and its metabolites as prophylactics for the prevention of stress-induced psychiatric disorders. Neuropharmacology. 2023;224:109345.","journal-title":"Neuropharmacology"},{"key":"2564_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.brainresbull.2022.02.008","volume":"182","author":"Y Wei","year":"2022","unstructured":"Wei Y, Wang T, Liao L, Fan X, Chang L, Hashimoto K. Brain-spleen axis in health and disease: a review and future perspective. Brain Res Bull. 2022;182:130\u201340.","journal-title":"Brain Res Bull."},{"key":"2564_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jad.2020.03.128","volume":"272","author":"J Zhang","year":"2020","unstructured":"Zhang J, Chang L, Pu Y, Hashimoto K. Abnormal expression of colony stimulating factor 1 receptor (CSF1R) and transcription factor PU.1 (SPI1) in the spleen from patients with major psychiatric disorders: a role of brain-spleen axis. J Affect Disord. 2020;272:110\u20135.","journal-title":"J Affect Disord."},{"key":"2564_CR43","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00406-019-01092-z","volume":"271","author":"K Zhang","year":"2021","unstructured":"Zhang K, Sakamoto A, Chang L, Qu Y, Wang S, Pu Y, et al. Splenic NKG2D confers resilience versus susceptibility in mice after chronic social defeat stress: beneficial effects of (R)-ketamine. Eur Arch Psychiatry Clin Neurosci. 2021;271:447\u201356.","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"2564_CR44","doi-asserted-by":"publisher","first-page":"100573","DOI":"10.1016\/j.bbih.2022.100573","volume":"27","author":"X Wan","year":"2022","unstructured":"Wan X, Eguchi A, Sakamoto A, Fujita Y, Yang Y, Qu Y, et al. Impact of broad-spectrum antibiotics on the gut\u2013microbiota\u2013spleen\u2013brain axis. Brain Behav Immun Health. 2022;27:100573.","journal-title":"Brain Behav Immun Health"},{"key":"2564_CR45","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jad.2022.08.087","volume":"317","author":"L Ma","year":"2022","unstructured":"Ma L, Zhang J, Fujita Y, Shinno-Hashimoto H, Shan J, Wan X, et al. Effects of spleen nerve denervation on depression-like phenotype, systemic inflammation, and abnormal composition of gut microbiota in mice after administration of lipopolysaccharide: a role of brain-spleen axis. J Affect Disord. 2022;317:156\u201365.","journal-title":"J Affect Disord."},{"key":"2564_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00878-3","volume":"10","author":"J Zhang","year":"2020","unstructured":"Zhang J, Ma L, Chang L, Pu Y, Qu Y, Hashimoto K. A key role of the subdiaphragmatic vagus nerve in the depression-like phenotype and abnormal composition of gut microbiota in mice after lipopolysaccharide administration. Transl Psychiatry. 2020;10:186.","journal-title":"Transl Psychiatry"},{"key":"2564_CR47","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1007\/s00213-021-05889-6","volume":"238","author":"J Zhang","year":"2021","unstructured":"Zhang J, Ma L, Wan X, Shan J, Qu Y, Hashimoto K. (R)-Ketamine attenuates LPS-induced endotoxin-derived delirium through inhibition of neuroinflammation. Psychopharmacology. 2021;238:2743\u201353.","journal-title":"Psychopharmacology"},{"key":"2564_CR48","doi-asserted-by":"publisher","first-page":"eabn8017.","DOI":"10.1126\/scisignal.abn8017","volume":"15","author":"A Ko","year":"2022","unstructured":"Ko A, Masataka I, Tomomi I, Tomonori T, Hiroko DM, Shun F, et al. Doxorubicin causes ferroptosis and cardiotoxicity by intercalating into mitochondrial DNA and disrupting Alas1-dependent heme synthesis. Sci Signal. 2022;15:eabn8017.","journal-title":"Sci Signal"},{"key":"2564_CR49","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/0006-291X(79)91133-1","volume":"88","author":"PS Ebert","year":"1979","unstructured":"Ebert PS, Hess RA, Frykholm BC, Tschudy DP. Succinylacetone, a potent inhibitor of heme biosynthesis: effect on cell growth, heme content and delta-aminolevulinic acid dehydratase activity of malignant murine erythroleukemia cells. Biochem Biophys Res Commun. 1979;88:1382\u201390.","journal-title":"Biochem Biophys Res Commun."},{"key":"2564_CR50","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1046\/j.1432-1327.1999.00843.x","volume":"266","author":"C Vijayasarathy","year":"1999","unstructured":"Vijayasarathy C, Damle S, Lenka N, Avadhani NG. Tissue variant effects of heme inhibitors on the mouse cytochrome c oxidase gene expression and catalytic activity of the enzyme complex. Eur J Biochem. 1999;266:191\u2013200.","journal-title":"Eur J Biochem."},{"key":"2564_CR51","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kr\u00e4mer","year":"2014","unstructured":"Kr\u00e4mer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014;30:523\u201330.","journal-title":"Bioinformatics"},{"key":"2564_CR52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0920-9964(99)00192-9","volume":"44","author":"EF Torrey","year":"2000","unstructured":"Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley Foundation brain collection and Neuropathology Consortium. Schizophr Res. 2000;44:151\u20135.","journal-title":"Schizophr Res."},{"key":"2564_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.95","volume":"7","author":"B Yang","year":"2017","unstructured":"Yang B, Ren Q, Zhang JC, Chen QX, Hashimoto K. Altered expression of BDNF, BDNF pro-peptide and their precursor proBDNF in brain and liver tissues from psychiatric disorders: rethinking the brain\u2013liver axis. Transl Psychiatry. 2017;7:e1128.","journal-title":"Transl Psychiatry"},{"key":"2564_CR54","doi-asserted-by":"publisher","first-page":"173500","DOI":"10.1016\/j.pbb.2022.173500","volume":"222","author":"Y Qu","year":"2023","unstructured":"Qu Y, Chang L, Ma L, Wan X, Hashimoto K. Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice. Pharmacol Biochem Behav. 2023;222:173500.","journal-title":"Pharmacol Biochem Behav."},{"key":"2564_CR55","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.bbamcr.2006.05.005","volume":"1763","author":"RS Ajioka","year":"2006","unstructured":"Ajioka RS, Phillips JD, Kushner JP. Biosynthesis of heme in mammals. Biochim Biophys Acta. 2006;1763:723\u201336.","journal-title":"Biochim Biophys Acta."},{"key":"2564_CR56","doi-asserted-by":"publisher","first-page":"118861","DOI":"10.1016\/j.bbamcr.2020.118861","volume":"1868","author":"G Layer","year":"2021","unstructured":"Layer G. Heme biosynthesis in prokaryotes. Biochim Biophys Acta Mol Cell Res. 2021;1868:118861.","journal-title":"Biochim Biophys Acta Mol Cell Res."},{"key":"2564_CR57","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1042\/BJ20040570","volume":"386","author":"TA Dailey","year":"2005","unstructured":"Dailey TA, Woodruff JH, Dailey HA. Examination of mitochondrial protein targeting of haem synthetic enzymes: in vivo identification of three functional haem-responsive motifs in 5-aminolaevulinate synthase. Biochem J. 2005;386:381\u20136.","journal-title":"Biochem J"},{"key":"2564_CR58","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/jha2.321","volume":"3","author":"C Berthou","year":"2021","unstructured":"Berthou C, Iliou JP, Barba D. Iron, neuro-bioavailability and depression. EJHaem. 2021;3:263\u201375.","journal-title":"EJHaem"},{"key":"2564_CR59","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.3390\/cells10102549","volume":"10","author":"DY Kang","year":"2021","unstructured":"Kang DY, Sp N, Jo ES, Lee JM, Jang KJ. New insights into the pivotal role of iron\/heme metabolism in TLR4\/NF-\u03baB signaling-mediated inflammatory responses in human monocytes. Cells. 2021;10:2549.","journal-title":"Cells"},{"key":"2564_CR60","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.intimp.2015.11.034","volume":"37","author":"M Fujino","year":"2016","unstructured":"Fujino M, Nishio Y, Ito H, Tanaka T, Li XK. 5-Aminolevulinic acid regulates the inflammatory response and alloimmune reaction. Int J Immunopharmacol. 2016;37:71\u20138.","journal-title":"Int J Immunopharmacol."},{"key":"2564_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02621-0","volume":"20","author":"HS Lee","year":"2020","unstructured":"Lee HS, Chao HH, Huang WT, Chen SCC, Yang HY. Psychiatric disorders risk in patients with iron deficiency anemia and association with iron supplementation medications: a nationwide database analysis. BMC Psychiatry. 2020;20:216.","journal-title":"BMC Psychiatry"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02564-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02564-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02564-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T15:32:54Z","timestamp":1690299174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02564-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2564"],"URL":"https:\/\/doi.org\/10.1038\/s41398-023-02564-6","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"21 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KH is the inventor of filed patent applications on \u201cThe use of <i>R<\/i>-Ketamine in the treatment of psychiatric diseases\u201d, \u201c(<i>S<\/i>)-norketamine and salt thereof as pharmaceutical\u201d, \u201c<i>R<\/i>-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder\u201d, \u201cPreventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases\u201d, and \u201c<i>R<\/i>-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder\u201d by the Chiba University. KH has also received speakers\u2019 honoraria, consultant fees, or research support from Abbott, Boehringer-Ingelheim, Daiichi-Sankyo, Meiji Seika Pharma, Seikagaku Corporation, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm and Perception Neuroscience. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"269"}}